JYMed Peptide Achieved Three Additional International Certifications

JYMed Peptide has established a comprehensive quality management system capable of consistently delivering products and services that meet customer expectations and comply with applicable laws and regulations. The achievement of ISO 9001 certification demonstrates that the company has well-defined processes and standards for internal management, enabling effective quality risk control, reducing errors and waste, and improving operational efficiency.

While pursuing economic benefits, the company has consistently adhered to environmental protection laws and regulations. The attainment of ISO 14001 certification showcases JYMed Peptide’s commitment to sustainable development, implementation of environmentally friendly practices, and fulfillment of its social responsibility as a high-tech enterprise in the biopharmaceutical industry.

The health and safety of employees remain a top priority at JYMed Peptide. From risk assessments to facility improvements, from staff training to emergency response systems, the company ensures that every employee can work in a safe and healthy environment. The recent acquisition of ISO 45001 certification reflects JYMed Peptide’s respect for the value of life and signifies that the company has reached an internationally advanced level in occupational health and safety management.

About JYMed

JYMed is a high-tech pharmaceutical company focused on the independent research, development, production, and commercialization of peptide-based products. We also offer comprehensive CDMO services, providing customized peptide solutions to global pharmaceutical, cosmetic, and veterinary clients.

Our product portfolio includes dozens of peptide APIs, with core products such as Semaglutide and Terlipressin having successfully completed U.S. FDA DMF filings.

Our wholly owned subsidiary, Hubei JXBio Pharmaceutical Co., Ltd., operates state-of-the-art peptide API production lines built to meet cGMP standards established by the U.S. FDA, and China’s NMPA. The facility houses 10 large-scale and pilot production lines, supported by a rigorous pharmaceutical quality management system (QMS) and a robust environmental health and safety (EHS) framework.

JXBio has passed GMP compliance inspections by both the U.S. FDA and China’s NMPA, and has been recognized by leading global pharmaceutical companies for its excellence in EHS management — a testament to our commitment to quality, safety, and environmental stewardship.

Core Business Areas
• Global registration and compliance for peptide APIs
• Veterinary and cosmetic peptides
• Custom peptide services (CRO, CMO, OEM)
• Peptide-drug conjugates (PDCs), including:
• Peptide-radionuclide
• Peptide-small molecule
• Peptide-protein
• Peptide-RNA therapeutics